GlassScriptPhysician profile
Jeffrey H Shaw
NPI 1851518955
$5,941.65
in general payments reported to CMS, 2019-2025
23 companies · $613 in 2025
The $613 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $783 · 2021: $1,029 · 2022: $1,232 · 2023: $931 · 2024: $824 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,236.42 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $732.00 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $702.58 | 2019-2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $665.54 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $465.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $298.76 | 2019-2025 | Bexsero |
| Pfizer INC. | $264.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $213.88 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Sobi, INC | $207.11 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $189.30 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $176.41 | 2019-2024 | |
| Cranial Technologies, INC | $170.62 | 2019-2025 | Doc Band |
| Adlon Therapeutics L.P. | $156.96 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $124.43 | 2021-2024 | Qelbree, Qelbree |
| Genentech USA, INC. | $97.32 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $73.88 | 2019-2025 | Relexxii |
| Cognoa, INC. | $51.44 | 2022 | |
| Dermira, INC. | $26.40 | 2020 | |
| Biomarin Pharmaceutical INC. | $23.97 | 2025 | Voxzogo 1.2mg |
| Avion Pharmaceuticals | $20.58 | 2023 | Methylphenidate Hydrochloride |
| Novartis Pharmaceuticals Corporation | $16.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.94 | 2021 | |
| Seqirus USA INC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.